Leveraging paired germline and somatic analysis to improve the classification of DDX41 variants [0.03%]
利用配对的体细胞和胚系分析来改善DDX41变异分类的方法
Maajid Mohi Ud Din Malik
Maajid Mohi Ud Din Malik
Pembrolizumab as first therapy for elderly or comorbid patients with classical Hodgkin lymphoma: Results of the phase 2 PLIMATH trial [0.03%]
派姆单抗作为老年或合并症的经典型霍奇金淋巴瘤患者一线治疗的疗效：PLIMATH II期临床试验结果
Michael J Dickinson,Leanne Berkahn,Judith Trotman et al.
Michael J Dickinson et al.
The cumulative effect of cytogenetic abnormalities on the outcomes of myeloma patients with del(17p) undergoing AHSCT in EBMT centres between 2016 and 2022 [0.03%]
2016年至2022年EBMT中心接受造血干细胞移植的del(17p)多发性骨髓瘤患者的细胞遗传学异常累积效应及其预后影响
Claire Comerford,Patrick J Hayden,Diderik-Jan Eikema et al.
Claire Comerford et al.
Minimal residual disease-guided ibrutinib and venetoclax in patients with chronic lymphocytic leukaemia and complex karyotype [0.03%]
用于携带复杂染色体核型的慢性淋巴细胞白血病患者的最小残留疾病指导下的伊布替尼和维纳妥拉疗法
Maria Kislova,Elena Dmitrieva,Elena Naumova et al.
Maria Kislova et al.
Complex karyotype (CK) is a strong predictor of early progression and poor survival in chronic lymphocytic leukaemia (CLL), including during targeted therapy. Minimal residual disease (MRD)-guided therapy may improve outcomes by enabling de...
Danburstotug, an anti-PD-L1 antibody, in relapsed/refractory extra-nodal natural killer/T-cell lymphoma: The phase 2 DISTINKT study [0.03%]
针对复发/难治结外自然杀伤细胞/T细胞淋巴瘤的抗PD-L1抗体丹布苏图格：DISTINKT二期研究
Won Seog Kim,Seok Jin Kim,Jae-Cheol Jo et al.
Won Seog Kim et al.
Relapsed/refractory extra-nodal natural killer/T-cell lymphoma (R/R ENKTL) has limited treatment options. Danburstotug, an antibody targeting programmed death-ligand 1 (PD-L1), was evaluated in adults with R/R ENKTL in a phase 2, open-label...
Clinical Trial
British journal of haematology. 2026 Oct;209(4):1638-1650. DOI:10.1111/bjh.70742 2026
Efficacy of a virtual reality headset in the management of severe pain during a vaso-occlusive crisis: A single-centre study in adults with sickle cell disease [0.03%]
头戴式虚拟现实装置在镰状细胞病患者血管阻塞危象时严重疼痛管理中的疗效：一项成人患者的单中心研究
Geoffrey Cheminet,Anne Corbasson,Kinda Al Kudsee et al.
Geoffrey Cheminet et al.
External validation of the AAA+ survival model in a large Chinese cohort with essential thrombocythaemia [0.03%]
中国原发性血小板增多症大样本队列中AAA+生存模型的外部验证研究
Lin Zhang,Wenjing Gu,Huan Dong et al.
Lin Zhang et al.
Triple A Plus (AAA+) is a recently proposed survival prediction model for essential thrombocythaemia (ET) intended for settings in which next-generation sequencing is unavailable. However, independent validation in non-Western populations r...
Treatment sequence with gilteritinib and allogeneic haematopoietic stem cell transplantation in relapsed/refractory FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukaemia patients: A multicentre real-world study [0.03%]
吉瑞替尼与allo-HSCT序贯治疗复发/难治型 FLT3 突变急性髓系白血病患者的多中心真实世界研究
Desiree Kunadt,Sven Zukunft,Christoph Röllig et al.
Desiree Kunadt et al.
Patients with relapsed or refractory acute myeloid leukaemia (r/r AML) harbouring FMS-like tyrosine kinase 3 (FLT3) mutations generally have poor prognosis and limited treatment options. The second-generation FLT3 inhibitor gilteritinib pro...
Multicenter Study
British journal of haematology. 2026 Oct;209(4):1783-1796. DOI:10.1111/bjh.70735 2026
Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real-life study from European Myeloma Network (EMN) Italy [0.03%]
来那度胺维持治疗后复发多发性骨髓瘤患者的补救治疗模式：欧洲骨髓瘤网络（EMN）意大利中心的真实世界研究
Gregorio Barilà,Angela Grassi,Valeria Ruocco et al.
Gregorio Barilà et al.
The extensive use of lenalidomide (Len) in the first-line treatment of multiple myeloma (MM) has resulted in an increased frequency of patients who have been exposed or are refractory to Len (Len-R) at first relapse. However, the outcome of...
Multicenter Study
British journal of haematology. 2026 Oct;209(4):1704-1714. DOI:10.1111/bjh.70751 2026
De novo JAK2-mutated acute myeloid leukaemia: Clinical outcomes and molecular features [0.03%]
从头出现JAK2突变的急性髓系白血病：临床结局与分子特征
Luca Guarnera,Emiliano Fabiani,Eleonora Lumia et al.
Luca Guarnera et al.